OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pulmonary Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors	84
Endotypes and phenotypes in obstructive sleep apnea	67
Pulmonary pathology of COVID-19: a review of autopsy studies	44
Chronic obstructive pulmonary disease and COVID-19: interrelationships	40
Coal mining and lung disease in the 21st century	40
Climate change and respiratory diseases: a 2020 perspective	36
Transmission of respiratory tract infections at mass gathering events	33
Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security	32
ABCA3 mutations in adult pulmonary fibrosis patients: a case series and review of literature	31
Viral respiratory infections: a cause of community-acquired pneumonia or a predisposing factor?	30
Recent advances in rheumatoid arthritis-associated interstitial lung disease	29
A clinical review of long-COVID with a focus on the respiratory system	25
MicroRNAs: future biomarkers and targets of therapy in asthma?	24
Household air pollution in India and respiratory diseases: current status and future directions	24
COVID-19: vaccines, efficacy and effects on variants	24
Obstructive sleep apnea and cancer: a complex relationship	20
Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician	20
Drug-induced sarcoidosis-like reactions	20
Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions	20
New guidelines for severe community-acquired pneumonia	19
Occupational lung diseases in the 21st century: the changing landscape and future challenges	18
Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline	18
Socioeconomic determinants and disparities in sarcoidosis	17
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world – opportunities and challenges	17
Genetics in sarcoidosis	17

A contemporary review of radiation pneumonitis	17
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies	17
Monitoring early stage lung disease in cystic fibrosis	16
Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment	16
TBX4 variants and pulmonary diseases: getting out of the ‘Box’	16
Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps	16
Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options	16
An update on sarcoidosis-associated pulmonary hypertension	15
The role of computed tomography scan in the diagnosis of COVID-19 pneumonia	15
The impact of fungal allergic sensitization on asthma	15
ICU preparedness in pandemics: lessons learned from the coronavirus disease-2019 outbreak	15
Obstructive sleep apnea in pulmonary fibrosis	14
Diabetes, insulin resistance, and asthma: a review of potential links	14
Sarcoidosis and autoimmunity	14
Telehealth and virtual health monitoring in cystic fibrosis	14
COVID-19: a new burden of respiratory disease among South African miners?	14
Risk stratification of indeterminate pulmonary nodules	14
Opioids and sleep	13
Pleuroparenchymal fibroelastosis	13
Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases	13
Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019	13
The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus	13
Yoga and Tai Chi: a mind–body approach in managing respiratory symptoms in obstructive lung diseases	13
COVID-19 and other respiratory tract infections at mass gathering religious and sporting events	13
Pneumococcal virulence factors in community-acquired pneumonia	12
Nontuberculous mycobacteria in cystic fibrosis	12
COVID-19 outcomes in people with cystic fibrosis	12
Does gender matter: sex-specific aspects of symptoms, outcome, and therapy of obstructive sleep apnea	12
Impact of obesity on pulmonary function: current understanding and knowledge gaps	12
Treatment of pulmonary exacerbations in cystic fibrosis	11
Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases	11
Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review	11
COVID-19 new diagnostics development: novel detection methods for SARS-CoV-2 infection and considerations for their translation to routine use	11
Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G × E) interaction studies	11
Asthma–COPD overlap: review of diagnosis and management	11
SMART - is it practical in the United States?	11
The current understanding and future directions for sputum microbiome profiling in chronic obstructive pulmonary disease	11
New pharmacologic agents for insomnia and hypersomnia	11
Unprecedented: the toxic synergism of Covid-19 and climate change	10
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections	10
Implementation of digital home monitoring and management of respiratory disease	10
Looking into the future of sarcoidosis: what is next for treatment?	10
Critical care of patients with pulmonary arterial hypertension	10
Atypical mycobacterial infections – management and when to treat	10
Pulmonary rehabilitation in a postcoronavirus disease 2019 world: feasibility, challenges, and solutions	10
Advances in molecular diagnostic tests for pneumonia	10
The evolving role of radiological imaging in cystic fibrosis	10
Update on sarcoidosis guidelines	10
Robotic bronchoscopy and future directions of interventional pulmonology	10
Respiratory and sleep-related complications of multiple system atrophy	10

Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis	10
Drug treatment of COVID-19 infection	10
Robotic bronchoscopy for peripheral pulmonary lesions: a convergence of technologies	9
Drug-resistant tuberculosis: advances in diagnosis and management	9
Telehealth in chronic obstructive pulmonary disease: before, during, and after the coronavirus disease 2019 pandemic	9
Immunology of sarcoidosis: old companions, new relationships	9
Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer	9
The role of PET in the management of sarcoidosis	9
Pulmonary adverse events following immune checkpoint inhibitors	9
Rapid eye movement predominant obstructive sleep apnoea: prognostic relevance and clinical approach	9
Vaping epidemic in US teens: problem and solutions	9
Obstructive lung diseases and allergic bronchopulmonary aspergillosis	9
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease	9
Epidemiology and real-life experience in progressive pulmonary fibrosis	9
Current practices in the management of central airway obstruction	9
Human global and population-specific genetic susceptibility to Mycobacterium tuberculosis infection and disease	9
Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review	9
Frailty in patients with interstitial lung disease	8
Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly	8
Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype	8
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum	8
Noninvasive positive pressure ventilation in stable patients with COPD	8
Lethal zoonotic coronavirus infections of humans – comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and se	8
Bronchoscopic diagnosis of peripheral lung lesions	8
Influenza: clinical aspects, diagnosis, and treatment	8
Beyond antibiotics for pulmonary nontuberculous mycobacterial disease	8
Alternative algorithms and devices in sleep apnoea diagnosis: what we know and what we expect	8
Pulmonary hypertension in majority countries: opportunities amidst challenges	8
Hit-hard and early versus step-up treatment in severe sarcoidosis	8